Among 31 analysts covering Diamondback Energy (NASDAQ:FANG), 25 have Buy rating, 0 Sell and 6 Hold. Therefore 81% are positive. Diamondback Energy had 61 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Overweight” rating by KeyBanc Capital Markets given on Friday, August 14. Topeka Capital Markets maintained it with “Buy” rating and $90.0 target in Wednesday, January 13 report. The firm has “Overweight” rating given on Tuesday, March 15 by JP Morgan. The firm has “Buy” rating by Deutsche Bank given on Wednesday, December 2. The firm has “Buy” rating by GMP Securities given on Wednesday, February 3. Canaccord Genuity upgraded Diamondback Energy Inc (NASDAQ:FANG) on Wednesday, July 20 to “Buy” rating. The stock of Diamondback Energy Inc (NASDAQ:FANG) has “Buy” rating given on Tuesday, October 20 by Canaccord Genuity. As per Thursday, December 3, the company rating was initiated by Nomura. The stock has “Buy” rating by Wunderlich on Thursday, January 14. Roth Capital maintained the stock with “Buy” rating in Tuesday, November 17 report. See Diamondback Energy Inc (NASDAQ:FANG) latest ratings:
16/12/2016 Broker: Drexel Hamilton Rating: Hold Initiates Coverage On
11/10/2016 Broker: KLR Group Rating: Buy Old Target: $126.00 New Target: $139.00 Maintain
11/10/2016 Broker: Wunderlich Rating: Buy Old Target: $110 New Target: $130 Maintain
10/10/2016 Broker: Williams Capital Group Rating: Hold Old Target: $105 New Target: $112 Maintain
06/10/2016 Broker: Mizuho Rating: Buy New Target: $105 Initiate
The stock of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) hit a new 52-week high and has $6.13 target or 6.00% above today’s $5.78 share price. The 8 months bullish chart indicates low risk for the $178.54M company. The 1-year high was reported on Mar, 31 by Barchart.com. If the $6.13 price target is reached, the company will be worth $10.71 million more. About 3.80 million shares traded or 973.39% up from the average. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has risen 206.74% since August 24, 2016 and is uptrending. It has outperformed by 197.88% the S&P500.
Analysts await Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to report earnings on May, 4. They expect $-0.27 earnings per share, up 22.86% or $0.08 from last year’s $-0.35 per share. After $-0.35 actual earnings per share reported by Conatus Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -22.86% EPS growth.
Among 4 analysts covering Conatus Pharma (NASDAQ:CNAT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conatus Pharma has $18 highest and $5 lowest target. $10.33’s average target is 78.72% above currents $5.78 stock price. Conatus Pharma had 7 analyst reports since September 22, 2015 according to SRatingsIntel. H.C. Wainwright maintained Conatus Pharmaceuticals Inc (NASDAQ:CNAT) rating on Tuesday, December 20. H.C. Wainwright has “Buy” rating and $18 target. The company was initiated on Friday, July 1 by Roth Capital. Stifel Nicolaus maintained the shares of CNAT in report on Thursday, November 5 with “Buy” rating. On Wednesday, November 9 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm earned “Buy” rating on Tuesday, December 20 by Stifel Nicolaus. As per Tuesday, September 22, the company rating was initiated by H.C. Wainwright.
Investors sentiment increased to 1.83 in Q4 2016. Its up 0.10, from 1.73 in 2016Q3. It increased, as 5 investors sold Conatus Pharmaceuticals Inc shares while 7 reduced holdings. 8 funds opened positions while 14 raised stakes. 4.44 million shares or 7.14% more from 4.14 million shares in 2016Q3 were reported. Millennium Mgmt Limited Liability Co holds 953,622 shares. The New York-based Goldman Sachs Grp Inc has invested 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). Blackrock Limited Liability Company owns 0% invested in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) for 2,650 shares. Kcg Incorporated reported 0.02% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). Blackrock Fund holds 0% or 49,008 shares in its portfolio. Barclays Public Ltd Liability Co owns 4,428 shares. Mpm Asset Management Ltd Liability, Massachusetts-based fund reported 1.19 million shares. Finance Architects reported 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). Geode Mngmt Lc owns 0% invested in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) for 86,460 shares. United Fincl Advisers Ltd Liability Com reported 154,578 shares. Citadel Ltd Company has invested 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). Reilly Fincl Advsr Llc owns 22,011 shares. Ellington Grp Inc Ltd Liability Corporation holds 0.02% of its portfolio in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) for 29,300 shares. Wells Fargo Company Mn has invested 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). Axa has invested 0.01% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT).
Conatus Pharmaceuticals Inc. is a biotechnology company. The company has market cap of $178.54 million. The Firm focuses on the development and commercialization of medicines to treat liver disease. It currently has negative earnings. The Firm operates through commercialization and development of pharmaceutical products segment.
Diamondback Energy, Inc. is an independent oil and natural gas company. The company has market cap of $9.29 billion. The Firm focuses on the acquisition, development, exploration and exploitation of unconventional onshore oil and natural gas reserves in the Permian Basin in West Texas. It currently has negative earnings. As of December 31, 2016, the Company’s total net acreage position in the Permian Basin was approximately 105,894 net acres.
Investors sentiment increased to 1.75 in 2016 Q4. Its up 0.47, from 1.28 in 2016Q3. It improved, as 32 investors sold Diamondback Energy Inc shares while 90 reduced holdings. 86 funds opened positions while 128 raised stakes. 90.81 million shares or 13.26% more from 80.18 million shares in 2016Q3 were reported. Tph Asset Limited Liability owns 2.3% invested in Diamondback Energy Inc (NASDAQ:FANG) for 225,650 shares. 3,001 are held by Metropolitan Life Co. Tobam stated it has 26,186 shares or 0.11% of all its holdings. Quantitative Inv Mgmt Lc reported 6,600 shares. Hodges Capital Mgmt stated it has 218,726 shares or 1.02% of all its holdings. First Bancorporation Of Omaha stated it has 0.25% in Diamondback Energy Inc (NASDAQ:FANG). Rainier Investment Management Ltd Company reported 0.77% stake. Winfield Assocs owns 30 shares or 0% of their US portfolio. Asset Management One Com Limited reported 147,299 shares. State Street Corp reported 0.02% of its portfolio in Diamondback Energy Inc (NASDAQ:FANG). Manufacturers Life Ins The reported 0% stake. Cambridge Investment Rech Advsrs has 2,115 shares. Lyon Street Capital Lc stated it has 1.24% of its portfolio in Diamondback Energy Inc (NASDAQ:FANG). Winslow Mgmt Ltd Liability Corporation has invested 0.95% of its portfolio in Diamondback Energy Inc (NASDAQ:FANG). Proshare Ltd Co holds 0.01% or 7,301 shares.
